Mouse Anti-LIPA Recombinant Antibody (CBT3381) (V2LY-0625-LY2071)

Go to compare Compare Online Inquiry
Tested Data
Request for COA
Datasheet Target References Q & As Review & reward Protocols Associated Products

Basic Information

Host Animal
Mouse
Clone
CBT3381
Application
WB
Immunogen
Purified recombinant fragment of LAL expressed in E. Coli.
Host Species
Mouse
Specificity
Human
Antibody Isotype
IgG2a
Clonality
Monoclonal Antibody
Application Notes
ApplicationNote
WB1:500-1:2,000
ELISA1:10,000

Formulations & Storage [For reference only, actual COA shall prevail!]

Format
Supernatant
Preservative
Sodium azide
Concentration
Batch dependent
Storage
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freezethaw cycles.
More Infomation

Target

Full Name
LIPA
Entrez Gene ID
UniProt ID
Function
Catalyzes the deacylation of triacylglyceryl and cholesteryl ester core lipids of endocytosed low density lipoproteins to generate free fatty acids and cholesterol.
Biological Process
Cell morphogenesisIEA:Ensembl
Cell population proliferationIEA:Ensembl
Homeostasis of number of cells within a tissueIEA:Ensembl
Inflammatory responseIEA:Ensembl
Lipid catabolic processIEA:UniProtKB-KW
Low-density lipoprotein particle clearanceTAS:Reactome
Lung developmentIEA:Ensembl
Sterol metabolic processManual Assertion Based On ExperimentIBA:GO_Central
Tissue remodelingIEA:Ensembl
Cellular Location
Lysosome
Involvement in disease
Wolman disease (WOD):
A severe manifestation of LIPA deficiency, leading to the accumulation of cholesteryl esters and triglycerides in most tissues of the body. WD occurs in infancy and is nearly always fatal before the age of 1 year.
Cholesteryl ester storage disease (CESD):
A mild manifestation of LIPA deficiency, leading to the accumulation of cholesteryl esters and triglycerides in most tissues of the body. It is characterized by late-onset.
PTM
Glycosylation is not essential for catalytic activity.

Korbelius, M., Kuentzel, K. B., Bradić, I., Vujić, N., & Kratky, D. (2023). Recent insights into lysosomal acid lipase deficiency. Trends in molecular medicine.

Gamblin, C., Rouault, C., Lacombe, A., Langa-Vives, F., Farabos, D., Lamaziere, A., ... & Dugail, I. (2021). Lysosomal acid lipase drives adipocyte cholesterol homeostasis and modulates lipid storage in obesity, independent of autophagy. Diabetes, 70(1), 76-90.

Pastores, G. M., & Hughes, D. A. (2020). Lysosomal acid lipase deficiency: therapeutic options. Drug design, development and therapy, 591-601.

Carotti, S., Aquilano, K., Valentini, F., Ruggiero, S., Alletto, F., Morini, S., ... & Vespasiani-Gentilucci, U. (2020). An overview of deregulated lipid metabolism in nonalcoholic fatty liver disease with special focus on lysosomal acid lipase. American Journal of Physiology-Gastrointestinal and Liver Physiology, 319(4), G469-G480.

Gomaraschi, M., Bonacina, F., & Norata, G. D. (2019). Lysosomal acid lipase: from cellular lipid handler to immunometabolic target. Trends in pharmacological sciences, 40(2), 104-115.

Li, F., & Zhang, H. (2019). Lysosomal acid lipase in lipid metabolism and beyond. Arteriosclerosis, thrombosis, and vascular biology, 39(5), 850-856.

Evans, T. D., Zhang, X., Clark, R. E., Alisio, A., Song, E., Zhang, H., ... & Razani, B. (2019). Functional characterization of lipa (lysosomal acid lipase) variants associated with coronary artery disease. Arteriosclerosis, thrombosis, and vascular biology, 39(12), 2480-2491.

Strebinger, G., Müller, E., Feldman, A., & Aigner, E. (2019). Lysosomal acid lipase deficiency–early diagnosis is the key. Hepatic medicine: evidence and research, 79-88.

Del Angel, G., Hutchinson, A. T., Jain, N. K., Forbes, C. D., & Reynders, J. (2019). Large‐scale functional LIPA variant characterization to improve birth prevalence estimates of lysosomal acid lipase deficiency. Human mutation, 40(11), 2007-2020.

Bychkov, I. O., Kamenets, E. A., Filatova, A. Y., Skoblov, M. Y., Mikhaylova, S. V., Strokova, T. V., ... & Zakharova, E. Y. (2019). The novel synonymous variant in LIPA gene affects splicing and causes lysosomal acid lipase deficiency. Molecular Genetics and Metabolism, 127(3), 212-215.

Ask a question We look forward to hearing from you.
0 reviews or Q&As
Loading...
Have you used Mouse Anti-LIPA Recombinant Antibody (CBT3381)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

online inquiry
Online Inquiry